OR
Oncology Reports
1021-335X
1791-2431
D.A. Spandidos
10.3892/or.2023.8505
OR-49-4-08505
Retraction
[Retracted] Isoquercitrin inhibits the progression of pancreatic cancer in vivo and in vitro by regulating opioid receptors and the mitogen‑activated protein kinase signalling pathway
ChenQuan
LiPing
XuYong
LiYang
TangBo
04
2023
20
02
2023
49
4
68
Copyright: © Chen et al.
2023
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.
Oncol Rep 33: 840–848, 2015; DOI: 10.3892/or.2014.3626
Subsequent to the publication of the above article, a concerned reader drew to our attention that the flow cytometric plots shown in Fig. 2 had previously appeared in another article published in the journal Oncology Reports [Huang G, Tang B, Tang K, Dong X, Deng J, Liao L, Liao Z, Yang H and He S: Isoquercitrin inhibits the progression of liver cancer in vivo and in vitro via the MAPK signalling pathway. Oncol Rep 31: 2377–2384, 2014], suggesting that data purportedly showing results obtained under different experimental conditions had been derived from the same original source.
Given the errors that were identified in the compilation of Fig. 2 in this article, and the fact that all the data in this figure had been re-used from a previously published source, the Editor of Oncology Reports has decided that this article should be retracted from the publication owing to a lack of overall confidence in the presented data. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive a satisfactory reply. The Editor apologizes to the readership for any inconvenience that might result from the retraction of this article.